Riding the Digital Health Wave: The L.E.K. Digital Excellence Framework

A divided government favors policies that have bipartisan support, or those that can be implemented via executive order.

Regardless of who is inaugurated on January 20, bipartisan priorities like lowering drug costs and increasing price transparency are expected to face…

The results of this study are reflective of news as of October 19, 2020. Overview of key policies and additional details on overall feasibility by…

In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations.

This survey offers a glimpse into how a pandemic has changed the general population’s sentiment on healthcare and resulting behavior.

Biopharmaceutical executives have engaged in extensive debates about the need for and effectiveness of value-based contracts (VBCs) ever since the…

Providers are on high alert due to the global impact of COVID-19. Current and potential future waves of infections, lockdowns and reopenings — and their…

Skyrocketing medical costs, clinical variation and outcomes that underindex those of other developed nations have risen to the forefront as key issues…

This report highlights how biopharma executives should adapt to the evolving biopharma landscape in both the nearer and longer term.

The following materials provide a snapshot of the unprecedented scope and speed of biopharma’s therapeutics research and development (R&D) response to…

The presence of artificial intelligence (AI) in life sciences is growing quickly as a result of multiple AI companies focusing on drug discovery and…

The Future of the Healthcare Industry: Q&A with L.E.K. Consulting's Evan Zeng